Evidence map›Paper›PMID 32285340›Full record

ReviewAdvances in therapy2020

Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.

Stefano Ballestri, Mariano Capitelli, Maria Cristina Fontana, Dimitriy Arioli, Elisa Romagnoli, Catia Graziosi, Amedeo Lonardo, Marco Marietta, Francesco Dentali, Giorgio Cioni

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. 2020 Clinical Update in Liver Transplantation.Journal of cardiothoracic and vascular anesthesia · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Stefano BallestriInternal Medicine Unit, Pavullo Hospital, Azienda USL, Modena, Italy. s.ballestri@ausl.mo.it.
Mariano CapitelliInternal Medicine Unit, Pavullo Hospital, Azienda USL, Modena, Italy.
Maria Cristina FontanaInternal Medicine Unit, Pavullo Hospital, Azienda USL, Modena, Italy.
Dimitriy ArioliInternal Medicine and Critical Care Unit, Azienda Ospedaliero-Universitaria, Modena, Italy.
Elisa RomagnoliInternal Medicine and Critical Care Unit, Azienda Ospedaliero-Universitaria, Modena, Italy.
Catia GraziosiInternal Medicine Unit, Pavullo Hospital, Azienda USL, Modena, Italy.
Amedeo LonardoMetabolic Syndrome Unit, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, Modena, Italy.
Marco MariettaHematology Unit, Azienda Ospedaliero-Universitaria, Modena, Italy.
Francesco DentaliDepartment of Clinical and Experimental Medicine, Insubria University, Varese, Italy.
Giorgio CioniInternal Medicine Unit, Pavullo Hospital, Azienda USL, Modena, Italy.
Policlinico di Modena · ITAzienda Unita' Sanitaria Locale Di Modena · ITUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for anticoagulant treatment of these conditions displaying a better efficacy/safety profile than vitamin-K antagonists, mainly due to significantly reduced risk of major bleeding, especially of intracranial haemorrhage. Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in developed countries showing a continuously growing prevalence. Nonalcoholic steatohepatitis (NASH), its evolutive form, will be the leading cause for liver transplantation by 2020. NAFLD is independently associated with an increased risk of abnormalities of cardiac structure and function, including cardiac rhythm disorders (mainly AF). Moreover, data suggest an increased risk of unprovoked VTE associated with NAFLD/NASH. Therefore, a growing number of patients with chronic liver disease (CLD) will be candidate for anticoagulant therapy in the near future. Cirrhosis of any etiology is characterized by an unstable thrombosis/bleeding haemostatic balance, making anticoagulant therapy particularly challenging in this condition. Given that patients with significant active liver disease and cirrhosis were excluded from all pivotal randomized controlled trials on DOACs, this comprehensive review aims at critically discussing real-world evidence, including the latest population studies, regarding the use of DOACs in patients with CLD/cirrhosis.

Indexed as

Administration, OralAnticoagulantsAtrial FibrillationHumansNon-alcoholic Fatty Liver DiseaseVenous ThromboembolismAnticoagulantsAtrial fibrillationCardiovascular diseaseCirrhosisDirect oral anticoagulantsFatty liverHeparinLiver diseaseStrokeThrombosisWarfarin

Identifiers

PMID32285340
PMCPMC7467481
OpenAlexW3015558415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.